Summary
The product Testosterone Cypionate, manufactured by Intex Pharma, underwent independent testing to verify its concentration and quality. The sample, identified by batch number 0-2331, was submitted by Intex Pharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis determined that the Testosterone Cypionate concentration was 216.43 mg/ml.
The testing process began on 8 October 2024, with the sample received on 22 October 2024, and analysis completed on 25 October 2024. While the results confirm the presence of Testosterone Cypionate, further scrutiny is necessary to ensure consistency across different batches. Independent third-party testing remains essential for comprehensive validation. This report is published as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Intex Pharma
- Product Name: Testosterone Cypionate
- Active Ingredient: Testosterone Cypionate
- Batch Number: 0-2331
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #51206
- Testing Ordered: 8 October 2024
- Sample Received: 22 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Intex Pharma (Manufacturer)
- Analysis Paid For By: Intex Pharma (Manufacturer)
Testing Results
- Specification: 200 mg/ml (as stated on the label)
- Measured Concentration: 216.43 mg/ml
- Accuracy: Slightly above the label claim
- Purity: Not provided
Verification Details
Verification URL: https://janoshik.com/tests/51206_6RPARAPSHB9Q
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that the tested product contains Testosterone Cypionate at a measured concentration of 216.43 mg/ml, which is slightly above the expected label claim of 200 mg/ml. Since this sample was submitted and funded by Intex Pharma, careful evaluation is needed to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, independent verification across multiple samples is recommended to establish broader reliability.
Conclusion
The analysis verifies the presence of Testosterone Cypionate at a concentration of 216.43 mg/ml, slightly above the labeled claim. While this result suggests good potency, additional testing across different batches would be beneficial to ensure consistent dosing. This report serves as an educational resource for harm reduction and informed decision-making in pharmaceutical use.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it still provides useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
